Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valbenazine - Neurocrine Biosciences

Drug Profile

Valbenazine - Neurocrine Biosciences

Alternative Names: INGREZZA; MT 5199; NBI-98854; Valbenazine-tosylate; VMAT2-inhibtor-Neurocrine-Biosciences

Latest Information Update: 22 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
  • Class 3-ring heterocyclic compounds; Amino acids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Phase III Huntington's disease
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Schizophrenia

Most Recent Events

  • 01 Nov 2019 Phase-III clinical trials in Huntington's disease in USA (PO) (NCT04102579)
  • 04 Oct 2019 Pooled efficacy and safety data from the phase III KINECT 3 and KINETIC 4 trial in Drug-induced dyskinesia released by Neurocrine Biosciences
  • 03 Oct 2019 Neurocrine Biosciences plans a phase III trial for Chorea with Huntington's disease (In adolescents, In adults, In the elderly) (PO, Capsule) (NCT04102579)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top